Enter your keywords

Antibacterial – MO opportunities

Overview At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and […]

Antibacterial drugs

This report looks at prescribing trends in primary care for antibacterial drugs at SICBL and ICB level with particular focus on prescribing volume of antibacterial agents such as cephalosporins, quinolones, macrolides and tetracyclines. Prescribing data is weighted with STAR-PU prescribing measures, and incorporates C. difficile rates and non-medical prescribing. If you have any queries about […]

Pylera for the eradication of Helicobacter Pylori infection

Overview Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour. Pylera is a new triple fixed-dose combination capsule containing  bismuth, metronidazole and tetracycline.  In combination with omeprazole, it […]

Antibiotic STAR-PU: Updated weightings for 2024 population

STAR-PUs were developed with the intended purpose of enabling adjustment to the cost-based medicines dispensed (prescribing) data to account for the demographic variables; age, sex and temporary resident status. However, changes in prescribing behaviour and trends, alongside demographics, over time, necessitate that this weighting is refreshed to ensure that it remains accurate.   The RDTC have […]

NHS Medicines Optimisation Opportunities Dashboard

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver […]

Antimicrobial prescribing across primary and secondary care

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees. This report combines primary and secondary care medicines usage data […]

Antimicrobial prescribing across the North of England

This bulletin provides an update on the current primary care antimicrobial prescribing trends at ICS level in the North of England. It specifically focuses on primary care prescribing, including the top 10 antibacterial drugs prescribed and the variation in the proportion of broad spectrum antibacterials prescribed across the ICSs.

Antibiotic Use in Children: Prescribing trends

This bulletin aims to highlight variation in total antimicrobial prescribing volume in children, defined here as 0-14 years. It specifically focuses on the proportion of unique patients prescribed regular antimicrobials throughout 12 months. National antimicrobial guidance, good practice guidance and resources are identified to help support good prescribing in practice. There are three versions of […]